中国のリバスチグミン市場2021-2027

【英語タイトル】China Rivastigmine Market Report & Forecast 2021-2027

QYResearchが出版した調査資料(QY993MC610)・商品コード:QY993MC610
・発行会社(調査会社):QYResearch
・発行日:2021年8月(※2024年版があります。お問い合わせください。)
・ページ数:約90
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:中国
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,400 ⇒換算¥503,200見積依頼/購入/質問フォーム
Multi User(1名様閲覧用)USD5,100 ⇒換算¥754,800見積依頼/購入/質問フォーム
Enterprise License(法人閲覧用)USD6,800 ⇒換算¥1,006,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Rivastigmine (sold under the trade name Exelon) is a acetylcholinesterase inhibitor used for the treatment of mild to moderate Alzheimer’s disease and Parkinson’s. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
This report contains market size and forecasts of Rivastigmine in China, including the following market information:

China Rivastigmine Market Revenue, 2016-2021, 2022-2027, ($ millions)

China Rivastigmine Market Sales, 2016-2021, 2022-2027, (K Units)

China top five Rivastigmine companies in 2020 (%)

The global Rivastigmine market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.

The China Rivastigmine market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.

QYResearch has surveyed the Rivastigmine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

China Rivastigmine Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)

China Rivastigmine Market Segment Percentages, By Type, 2020 (%)

Oral

Transdermal Patch

China Rivastigmine Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)

China Rivastigmine Market Segment Percentages, By Application, 2020 (%)

Alzheimer’s Disease

Parkinson’s Disease

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Rivastigmine revenues in China market, 2016-2021 (Estimated), ($ millions)

Key companies Rivastigmine revenues share in China market, 2020 (%)

Key companies Rivastigmine sales in China market, 2016-2021 (Estimated), (K Units)

Key companies Rivastigmine sales share in China market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Sun Pharmaceutical

Alvogen

Mylan Pharmaceuticals

Teva

Dr. Reddy’s Laboratories

Orchid Healthcare

APOTEX

Alembic Pharmaceuticals

MACLEODS

Cadila Pharmaceuticals

Aurobindo Pharma

Ajanta Pharma

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Rivastigmine Market Definition

1.2 Market Segments

1.2.1 Segment by Type

1.2.2 Segment by Application

1.3 China Rivastigmine Market Overview

1.4 Methodology & Sources of Information

1.4.1 Research Methodology

1.4.2 Research Process

1.4.3 Base Year

2 China Rivastigmine Overall Market Size

2.1 China Rivastigmine Market Size: 2021 VS 2027

2.2 China Rivastigmine Revenue, Prospects & Forecasts: 2016-2027

2.3 China Rivastigmine Sales: 2016-2027

3 Company Landscape

3.1 Top Rivastigmine Players in China Market

3.2 Top China Rivastigmine Companies Ranked by Revenue

3.3 China Rivastigmine Revenue by Companies

3.4 China Rivastigmine Sales by Companies

3.5 China Rivastigmine Price by Manufacturer (2016-2021)

3.6 Top 3 and Top 5 Rivastigmine Companies in China Market, by Revenue in 2020

3.7 Manufacturers Rivastigmine Product Type

3.8 Tier 1, Tier 2 and Tier 3 Rivastigmine Players in China Market

3.8.1 List of Tier 1 Rivastigmine Companies in China

3.8.2 List of Tier 2 and Tier 3 Rivastigmine Companies in China

4 Sights by Type

4.1 Overview

4.1.1 By Type – China Rivastigmine Market Size Markets, 2021 & 2027

4.1.2 Oral

4.1.3 Transdermal Patch

4.2 By Type – China Rivastigmine Revenue & Forecasts

4.2.1 By Type – China Rivastigmine Revenue, 2016-2021

4.2.2 By Type – China Rivastigmine Revenue, 2022-2027

4.2.3 By Type – China Rivastigmine Revenue Market Share, 2016-2027

4.3 By Type – China Rivastigmine Sales & Forecasts

4.3.1 By Type – China Rivastigmine Sales, 2016-2021

4.3.2 By Type – China Rivastigmine Sales, 2022-2027

4.3.3 By Type – China Rivastigmine Sales Market Share, 2016-2027

4.4 By Type – China Rivastigmine Price (Manufacturers Selling Prices), 2016-2027

5 Sights by Application

5.1 Overview

5.1.1 By Application – China Rivastigmine Market Size, 2021 & 2027

5.1.2 Alzheimer’s Disease

5.1.3 Parkinson’s Disease

5.2 By Application – China Rivastigmine Revenue & Forecasts

5.2.1 By Application – China Rivastigmine Revenue, 2016-2021

5.2.2 By Application – China Rivastigmine Revenue, 2022-2027

5.2.3 By Application – China Rivastigmine Revenue Market Share, 2016-2027

5.3 By Application – China Rivastigmine Sales & Forecasts

5.3.1 By Application – China Rivastigmine Sales, 2016-2021

5.3.2 By Application – China Rivastigmine Sales, 2022-2027

5.3.3 By Application – China Rivastigmine Sales Market Share, 2016-2027

5.4 By Application – China Rivastigmine Price (Manufacturers Selling Prices), 2016-2027

6 Manufacturers & Brands Profiles

6.1 Novartis

6.1.1 Novartis Corporation Information

6.1.2 Novartis Overview

6.1.3 Novartis Rivastigmine Sales and Revenue in China Market (2016-2021)

6.1.4 Novartis Rivastigmine Product Description

6.1.5 Novartis Recent Developments

6.2 Sun Pharmaceutical

6.2.1 Sun Pharmaceutical Corporation Information

6.2.2 Sun Pharmaceutical Overview

6.2.3 Sun Pharmaceutical Rivastigmine Sales and Revenue in China Market (2016-2021)

6.2.4 Sun Pharmaceutical Rivastigmine Product Description

6.2.5 Sun Pharmaceutical Recent Developments

6.3 Alvogen

6.3.1 Alvogen Corporation Information

6.3.2 Alvogen Overview

6.3.3 Alvogen Rivastigmine Sales and Revenue in China Market (2016-2021)

6.3.4 Alvogen Rivastigmine Product Description

6.3.5 Alvogen Recent Developments

6.4 Mylan Pharmaceuticals

6.4.1 Mylan Pharmaceuticals Corporation Information

6.4.2 Mylan Pharmaceuticals Overview

6.4.3 Mylan Pharmaceuticals Rivastigmine Sales and Revenue in China Market (2016-2021)

6.4.4 Mylan Pharmaceuticals Rivastigmine Product Description

6.4.5 Mylan Pharmaceuticals Recent Developments

6.5 Teva

6.5.1 Teva Corporation Information

6.5.2 Teva Overview

6.5.3 Teva Rivastigmine Sales and Revenue in China Market (2016-2021)

6.5.4 Teva Rivastigmine Product Description

6.5.5 Teva Recent Developments

6.6 Dr. Reddy’s Laboratories

6.6.1 Dr. Reddy’s Laboratories Corporation Information

6.6.2 Dr. Reddy’s Laboratories Overview

6.6.3 Dr. Reddy’s Laboratories Rivastigmine Sales and Revenue in China Market (2016-2021)

6.6.4 Dr. Reddy’s Laboratories Rivastigmine Product Description

6.6.5 Dr. Reddy’s Laboratories Recent Developments

6.7 Orchid Healthcare

6.7.1 Orchid Healthcare Corporation Information

6.7.2 Orchid Healthcare Overview

6.7.3 Orchid Healthcare Rivastigmine Sales and Revenue in China Market (2016-2021)

6.7.4 Orchid Healthcare Rivastigmine Product Description

6.7.5 Orchid Healthcare Recent Developments

6.8 APOTEX

6.8.1 APOTEX Corporation Information

6.8.2 APOTEX Overview

6.8.3 APOTEX Rivastigmine Sales and Revenue in China Market (2016-2021)

6.8.4 APOTEX Rivastigmine Product Description

6.8.5 APOTEX Recent Developments

6.9 Alembic Pharmaceuticals

6.9.1 Alembic Pharmaceuticals Corporation Information

6.9.2 Alembic Pharmaceuticals Overview

6.9.3 Alembic Pharmaceuticals Rivastigmine Sales and Revenue in China Market (2016-2021)

6.9.4 Alembic Pharmaceuticals Rivastigmine Product Description

6.9.5 Alembic Pharmaceuticals Recent Developments

6.10 MACLEODS

6.10.1 MACLEODS Corporation Information

6.10.2 MACLEODS Overview

6.10.3 MACLEODS Rivastigmine Sales and Revenue in China Market (2016-2021)

6.10.4 MACLEODS Rivastigmine Product Description

6.10.5 MACLEODS Recent Developments

6.11 Cadila Pharmaceuticals

6.11.1 Cadila Pharmaceuticals Corporation Information

6.11.2 Cadila Pharmaceuticals Overview

6.11.3 Cadila Pharmaceuticals Rivastigmine Sales and Revenue in China Market (2016-2021)

6.11.4 Cadila Pharmaceuticals Rivastigmine Product Description

6.11.5 Cadila Pharmaceuticals Recent Developments

6.12 Aurobindo Pharma

6.12.1 Aurobindo Pharma Corporation Information

6.12.2 Aurobindo Pharma Overview

6.12.3 Aurobindo Pharma Rivastigmine Sales and Revenue in China Market (2016-2021)

6.12.4 Aurobindo Pharma Rivastigmine Product Description

6.12.5 Aurobindo Pharma Recent Developments

6.13 Ajanta Pharma

6.13.1 Ajanta Pharma Corporation Information

6.13.2 Ajanta Pharma Overview

6.13.3 Ajanta Pharma Rivastigmine Sales and Revenue in China Market (2016-2021)

6.13.4 Ajanta Pharma Rivastigmine Product Description

6.13.5 Ajanta Pharma Recent Developments

7 China Rivastigmine Production Capacity, Analysis

7.1 China Rivastigmine Production Capacity, 2016-2027

7.2 Rivastigmine Production Capacity of Key Manufacturers in China Market

8 Key Market Trends, Opportunity, Drivers and Restraints

8.1 Market Opportunities & Trends

8.2 Market Drivers

8.3 Market Restraints

9 Rivastigmine Supply Chain Analysis

9.1 Rivastigmine Industry Value Chain

9.2 Rivastigmine Upstream Market

9.3 Rivastigmine Downstream and Clients

9.4 Marketing Channels Analysis

9.4.1 Marketing Channels

9.4.2 Rivastigmine Distributors and Sales Agents in China Market

10 Conclusion

11 Appendix

11.1 Note

11.2 Examples of Clients

11.3 Author Details

11.4 Disclaimer



★調査レポート[中国のリバスチグミン市場2021-2027] (コード:QY993MC610)販売に関する免責事項を必ずご確認ください。
★調査レポート[中国のリバスチグミン市場2021-2027]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆